Print this page Close this page

Printer Friendly

Printed from http://www.researchandmarkets.com/reports/1821586

AKELA Pharma Inc. - Product Pipeline Review - Q1 2011

Description:
AKELA Pharma Inc. – Product Pipeline Review – Q1 2011

Summary

Global Market Direct’s pharmaceuticals report, “AKELA Pharma Inc. - Product Pipeline Review - Q1 2011” provides data on the company’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- AKELA Pharma Inc. - Brief company overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of AKELA Pharma Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of AKELA Pharma Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the AKELA Pharma Inc.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate AKELA Pharma Inc.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of AKELA Pharma Inc. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the AKELA Pharma Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with AKELA Pharma Inc..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of AKELA Pharma Inc. and identify potential opportunities in those areas.
Contents:


List of Tables
List of Figures
AKELA Pharma Inc. Snapshot
AKELA Pharma Inc. Overview
Key Information
Key Facts
AKELA Pharma Inc. – Research and Development Overview
Key Therapeutic Areas
AKELA Pharma Inc. – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
AKELA Pharma Inc. – Pipeline Products Glance
AKELA Pharma Inc. – Late Stage Pipeline
Phase III Products/Combination Treatment Modalities
AKELA Pharma Inc. Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
AKELA Pharma Inc. – Drug Profiles
Fentanyl TAIFUN
Product Description
Mechanism of Action
R&D Progress
AKL-0707
Product Description
Mechanism of Action
R&D Progress
CGRP
Product Description
Mechanism of Action
R&D Progress
EDACS Based Opioid Drug
Product Description
Mechanism of Action
R&D Progress
AKELA Pharma Inc. – Pipeline Analysis
AKELA Pharma Inc. – Pipeline Products by Therapeutic Class
AKELA Pharma Inc. - Pipeline Products By Target
AKELA Pharma Inc. – Pipeline Products by Route of Administration
AKELA Pharma Inc. – Pipeline Products by Molecule Type
AKELA Pharma Inc. - Dormant Projects
AKELA Pharma Inc. - Discontinued Pipeline Products
Discontinued Pipeline Product Profiles
HspE7 + Poly-ICLC
AKELA Pharma Inc. – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
AKELA Pharma Inc. - Key Manufacturing Facilities
Financial Deals Landscape
AKELA Pharma Inc., Deals Volume Summary, 2004 to YTD 2011
AKELA Pharma Inc., Deals Summary By Region, 2004 to YTD 2011
AKELA Pharma Inc., Deals Summary, 2004 to YTD 2011
AKELA Pharma Inc. Detailed Deal Summary
Acquisition
AKELA Pharma Acquires Pharmaform
LAB International Acquires Focus Inhalation
Equity Offering
Akela Pharma Completes Public Offering Of $10.23 Million
Nventa Completes Private Placement Of $14 Million
AKELA Pharma Completes Private Placement Of $23 Million
AKELA Pharma Completes Initial Public Offering Of $28.13 Million
AKELA Pharma Completes Private Placement Of $10.65 Million
Akela Pharma Completes Private Placement Of $7.96 Million
AKELA Pharma Withdraws Its Initial Public Offering
Akela Pharma Enters Into A Development Agreement With Undisclosed Pharmaceutical Company
Licensing Agreements
Akela Pharma Extends Its License And Development With Janssen Pharmaceutica
AKELA Pharma Enters Into Licensing And Development Agreement With Janssen Pharmaceutica
Akela Pharma Enters Into A Licensing And Development Agreement With Teikoku Seiyaku
Auxilium Pharmaceuticals Enters Into Worldwide Licensing Agreement With PharmaForm
AKELA Pharma Enters Into Licensing Agreement With SK Chemicals
Akela Pharma Terminates Its Agreement With Grupo Ferrer Internacional
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
AKELA Pharma Inc. – Pipeline by Therapy Area and Indication, 2011
AKELA Pharma Inc. – Pipeline by Stage of Development, 2011
AKELA Pharma Inc. – Monotherapy Products in Pipeline, 2011
AKELA Pharma Inc. – Phase III, 2011
AKELA Pharma Inc. - Phase II, 2011
AKELA Pharma Inc. - Phase I, 2011
AKELA Pharma Inc. - Pipeline By Therapeutic Class, 2011
AKELA Pharma Inc. - Pipeline By Target, 2011
AKELA Pharma Inc. – Pipeline By Route of Administration, 2011
AKELA Pharma Inc. – Pipeline By Molecule Type, 2011
AKELA Pharma Inc. - Dormant Developmental Projects, 2010
AKELA Pharma Inc. - Discontinued Pipeline Products, 2010
AKELA Pharma Inc., Subsidiaries
AKELA Pharma Inc., Key Manufacturing Facilities
AKELA Pharma Inc., Deals Summary, 2004 to YTD 2011
AKELA Pharma Inc., Deals Summary by Region, 2004 to YTD 2011
AKELA Pharma Inc., Deals Summary, 2004 to YTD 2011

List of Figures
AKELA Pharma Inc. – Pipeline by Therapy Area and Indication, 2011
AKELA Pharma Inc. – Pipeline by Stage of Development, 2011
AKELA Pharma Inc. – Monotherapy Products in Pipeline, 2011
AKELA Pharma Inc. – Pipeline By Therapeutic Class, 2011
AKELA Pharma Inc. - Pipeline By Target, 2011
AKELA Pharma Inc. – Pipeline By Route of Administration, 2011
AKELA Pharma Inc. – Pipeline By Molecule Type, 2011
Ordering:

Order Online - visit http://www.researchandmarkets.com/reports/1582661

Order by Fax - using the order form below

Order By Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.

Page 1 of 2
Printed Thursday, May 23, 2013
9:44:41 PM

Fax order form

To place a fax order simply print this form, fill in and fax the completed form to the number below. If you have any questions please email help@researchandmarkets.net

Order information

Please verify that the product information is correct and select the format you require.

Product name

AKELA Pharma Inc. - Product Pipeline Review - Q1 2011

Web Address

http://www.researchandmarkets.com/reports/1821586

Office Code

OC8DIQSNUNURWZ

Report Formats

Please enter the quantity of the report format you require.

Format Quantity Price
Electronic (PDF) - Single User EURO€ 384.00
Electronic (PDF) - Site License EURO€ 769.00
Electronic (PDF) - Enterprisewide EURO€ 1,153.00

Contact information

Please enter all the information below in block capitals.

Title:
Mr Mrs Dr Miss Ms Prof
First Name:
Last Name:
Email Address:
Job Title:
Organisation:
Address:
City:
Postal / Zip Code:
Country:
Phone Number:
Fax Number:

Please fax this form to:
(646) 607-1907 or (646) 964-6609 (from USA)
+353-1-481-1716 or +353-1-653-1571 (from Rest of World)

Page 2 of 2
Printed Thursday, May 23, 2013
9:44:41 PM

Payment information

Please indicate the payment method you would like to use by selecting the appropriate box.

Pay by Credit Card:

American Express

Diners Club

Master Card

Visa

Cardholder's Name:
Cardholder's Signature:
Expiry Date:
/
Card Number:
CVV Security Code:
Issue date:
/ (Diners Club only)
Pay by Check:

Please post the check, accompanied by this form, to:

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.

Pay by Wire Transfer:

Please transfer funds to:

Account Number:
83313083
Sort Code:
98-53-30
Swift Code:
ULSBIE2D
IBAN Number:
IE78ULSB98533083313083
Bank Address:
Ulster Bank,
27-35 Main Street
Blackrock,
Co. Dublin
Ireland.

If you have a Marketing Code please enter it below:

Marketing Code:

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 (from USA)
+353-1-481-1716 or +353-1-653-1571 (from Rest of World)